drugset / Trial / NCT07221188
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
Timeline
- Start
- 2025-12-12
- Primary completion
- 2028-03-24
- Completion
- 2028-03-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efimosfermin alfa | Unknown | — | — |